NO20055152D0 - Karbonstyrilderivater og humor stabiliserende midler for behandling av humor forstyrrelser - Google Patents

Karbonstyrilderivater og humor stabiliserende midler for behandling av humor forstyrrelser

Info

Publication number
NO20055152D0
NO20055152D0 NO20055152A NO20055152A NO20055152D0 NO 20055152 D0 NO20055152 D0 NO 20055152D0 NO 20055152 A NO20055152 A NO 20055152A NO 20055152 A NO20055152 A NO 20055152A NO 20055152 D0 NO20055152 D0 NO 20055152D0
Authority
NO
Norway
Prior art keywords
humor
stabilizers
treatment
disorders
styrene derivatives
Prior art date
Application number
NO20055152A
Other languages
English (en)
Other versions
NO332764B1 (no
NO20055152L (no
Inventor
Tetsuro Kikuchi
Taro Iwamoto
Tsuyoshi Hirose
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33490596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20055152(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of NO20055152D0 publication Critical patent/NO20055152D0/no
Publication of NO20055152L publication Critical patent/NO20055152L/no
Publication of NO332764B1 publication Critical patent/NO332764B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
NO20055152A 2003-05-23 2005-11-03 Preparat omfattende karbostyril-derivat og stemningsleie-stabilisator, samt anvendelse derav NO332764B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47337803P 2003-05-23 2003-05-23
PCT/US2004/013308 WO2004105682A2 (en) 2003-05-23 2004-05-19 Carbostyril derivatives and mood stabilizers for treating mood disorders

Publications (3)

Publication Number Publication Date
NO20055152D0 true NO20055152D0 (no) 2005-11-03
NO20055152L NO20055152L (no) 2005-12-07
NO332764B1 NO332764B1 (no) 2013-01-07

Family

ID=33490596

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055152A NO332764B1 (no) 2003-05-23 2005-11-03 Preparat omfattende karbostyril-derivat og stemningsleie-stabilisator, samt anvendelse derav

Country Status (27)

Country Link
US (5) US9125939B2 (no)
EP (2) EP1626721B1 (no)
JP (2) JP4693778B2 (no)
KR (1) KR100881046B1 (no)
CN (5) CN102000336A (no)
AU (1) AU2004243096B2 (no)
BR (1) BRPI0410786A (no)
CA (1) CA2526562C (no)
CO (1) CO5630025A2 (no)
CY (1) CY1118313T1 (no)
DK (1) DK1626721T3 (no)
EC (1) ECSP056182A (no)
ES (1) ES2609382T3 (no)
GE (1) GEP20084567B (no)
HU (1) HUE030014T2 (no)
IL (3) IL171414A (no)
LT (1) LT1626721T (no)
MX (1) MXPA05012538A (no)
NO (1) NO332764B1 (no)
NZ (1) NZ542985A (no)
PL (1) PL1626721T3 (no)
PT (1) PT1626721T (no)
RU (1) RU2359675C2 (no)
TW (1) TWI342776B (no)
UA (1) UA92453C2 (no)
WO (1) WO2004105682A2 (no)
ZA (1) ZA200508306B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) * 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
NZ556779A (en) 2002-12-27 2008-12-24 Otsuka Pharma Co Ltd Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
ES2294979T1 (es) 2005-01-27 2008-04-16 Alembic Limited Formulacion de levetiracetam de liberacion prolongada.
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
HRP20141185T1 (hr) * 2005-07-26 2015-01-30 Ucb Pharma Sa Farmaceutski pripravci koji sadrže levetiracetam i proces za njihovu pripremu
US20080014271A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
JP5466147B2 (ja) * 2007-05-21 2014-04-09 レビバ ファーマシューティカルズ，インコーポレーテッド キノリノン系非定型抗精神病薬剤の組成物、合成、及び使用方法
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
DK2400968T3 (da) 2009-02-26 2017-01-02 Reviva Pharmaceuticals Inc Sammensætninger, syntese og fremgangsmåder til anvendelse af arylpiperazinderivater
CA2937222C (en) * 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
ES3031438T3 (en) 2009-06-25 2025-07-08 Alkermes Pharma Ireland Ltd Heterocyclic compounds for the treatment of neurological and psychological disorders
WO2011163594A2 (en) * 2010-06-24 2011-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
WO2012109491A1 (en) * 2011-02-09 2012-08-16 The Johns Hopkins University Methods and compositions for improving cognitive function
US9034867B2 (en) 2011-03-18 2015-05-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
WO2013088255A1 (en) 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
JP6219918B2 (ja) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
WO2013142205A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
WO2013142198A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
EP3718536A1 (en) 2012-09-19 2020-10-07 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CN103550778B (zh) * 2013-11-18 2015-12-30 四川科瑞德制药有限公司 一种治疗情感性精神障碍疾病的药物组合物
EP3119399A4 (en) 2014-03-20 2017-09-27 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
NZ738682A (en) 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam
CN108623520A (zh) * 2017-03-16 2018-10-09 重庆医药工业研究院有限责任公司 阿立哌唑缩醛月桂酸酯的制备方法
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
JP7211136B2 (ja) * 2019-02-14 2023-01-24 ニプロ株式会社 錠剤、および、その製造方法
US20240009181A1 (en) * 2022-07-08 2024-01-11 Jason Eric Schiffman Method for the treatment and prophylaxis of substance-related and/or addictive disorders including substance/medication-induced depressive disorders, bipolar and related disorders, and anxiety disorders and compositions useful for the same
CN115991674B (zh) * 2022-12-14 2025-03-18 杭州同舟生物技术有限公司 一种阿立哌唑人工半抗原、人工抗原及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
JPH04284524A (ja) * 1991-03-14 1992-10-09 Matsushita Electric Ind Co Ltd キー入力装置
WO1997035584A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
NZ507981A (en) * 1998-05-29 2003-10-31 Lilly Co Eli Combination therapy for treatment of bipolar disorders
US20030027817A1 (en) 1998-05-29 2003-02-06 Tollefson Gary Dennis Combination therapy for treatment of bipolar disorders
ES2238999T3 (es) 1999-02-24 2005-09-16 University Of Cincinnati Uso de derivados de sulfamato para tratar trastornos en el control de los impulsos.
EP1165083A2 (en) 1999-04-06 2002-01-02 Sepracor Inc. Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites
JP2004517112A (ja) * 2001-01-02 2004-06-10 ファルマシア・アンド・アップジョン・カンパニー 新規薬物コンビネーション
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
WO2002087590A1 (en) * 2001-04-26 2002-11-07 Ortho-Mcneil Pharmaceutical, Inc. Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
MXPA04007752A (es) * 2002-02-08 2005-06-17 Abbott Lab Terapia de combinacion para tratamiento de esquizofrenia.
NZ556779A (en) * 2002-12-27 2008-12-24 Otsuka Pharma Co Ltd Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
EP1633400A2 (en) * 2003-05-16 2006-03-15 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines

Also Published As

Publication number Publication date
US20200246332A1 (en) 2020-08-06
AU2004243096B2 (en) 2008-12-18
JP2011093920A (ja) 2011-05-12
EP1626721A2 (en) 2006-02-22
CY1118313T1 (el) 2017-06-28
NO332764B1 (no) 2013-01-07
KR20060021857A (ko) 2006-03-08
NZ542985A (en) 2009-04-30
NO20055152L (no) 2005-12-07
PL1626721T3 (pl) 2017-05-31
US20210308126A1 (en) 2021-10-07
WO2004105682A3 (en) 2005-05-12
CN102172402A (zh) 2011-09-07
CN102172401A (zh) 2011-09-07
KR100881046B1 (ko) 2009-01-30
RU2359675C2 (ru) 2009-06-27
ES2609382T3 (es) 2017-04-20
EP1626721A4 (en) 2008-06-18
GEP20084567B (en) 2008-12-25
JP4693778B2 (ja) 2011-06-01
CN102166359A (zh) 2011-08-31
CA2526562C (en) 2011-06-28
MXPA05012538A (es) 2006-02-22
US20240024310A1 (en) 2024-01-25
CN102000336A (zh) 2011-04-06
TW200426146A (en) 2004-12-01
PT1626721T (pt) 2017-02-28
US20160030423A1 (en) 2016-02-04
US20070031513A1 (en) 2007-02-08
BRPI0410786A (pt) 2006-06-20
IL211529A0 (en) 2011-05-31
ZA200508306B (en) 2007-03-28
WO2004105682A2 (en) 2004-12-09
EP2601953A1 (en) 2013-06-12
HUE030014T2 (en) 2017-04-28
EP1626721B1 (en) 2016-12-07
DK1626721T3 (en) 2017-01-23
TWI342776B (en) 2011-06-01
CO5630025A2 (es) 2006-04-28
RU2005140285A (ru) 2006-06-10
AU2004243096A1 (en) 2004-12-09
IL171414A (en) 2015-03-31
JP2007503460A (ja) 2007-02-22
LT1626721T (lt) 2017-01-25
US9125939B2 (en) 2015-09-08
IL230025A0 (en) 2014-01-30
CN1794994A (zh) 2006-06-28
UA92453C2 (ru) 2010-11-10
CA2526562A1 (en) 2004-12-09
ECSP056182A (es) 2006-04-19

Similar Documents

Publication Publication Date Title
NO20052796D0 (no) Indolylpyrazinonderivater anvendelige for behandling av hyper-proliferative forstyrrelser og sykdommer assosiert med angiogenese
IL230025A0 (en) Carbosteril history and mood stabilizers for the treatment of mood disorder
HUS1500034I1 (hu) Indolidon-származékok fibrózisos betegségek kezelésére vagy megelõzésére
GB0312832D0 (en) 2-amino-pyridine derivatives useful for the treatment of diseases
NO20043237L (no) Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser
IS2722B (is) 1, 2, 3, 4- Tetrasetin indól til meðhöndlunar á öndunarfærasjúkdómum
LTC1562603I2 (lt) Nauji vaistai, skirti lėtinių obstrukcinių plaučių ligų gydymui
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
DK1663978T3 (da) Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
NO20050570L (no) Nye forbindelser, preparater og fremgangsmater for behandling av inflammasjonssykdommer og -tilstander
SI1572215T1 (sl) Benzo(d)azepinski derivati za zdravljenje nevroloĺ kih motenj
IS7840A (is) 3-(3,5-díoxó-4,5-díhýdró-3H-(1,2,4)tríasín-2-ýl)-bensamíð afleiður sem P2X7-hindrar til notkunar í meðferð á bólguvaldandi sjúkdómum
DE602006021323D1 (de) Pyridinderivate und ihre verwendung bei der behandlung psychotischer erkrankungen
EE200200442A (et) Piperasiini ja piperidiini derivaadid neuronaalsete kahjustuste raviks
NO20026263L (no) Sulfonyl-pyrrolidin-derivater anvendelige for behandling av neurologiske forstyrrelser
IL183656A0 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
SI1487828T1 (sl) Morfolinil-sečninski derivati za uporabo pri zdravljenu vnetnih bolezni
NO20052009D0 (no) Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom
NO20044250L (no) Heterocykliske amid-derivativer for behandling av diabetes og andre sykdommer
NO20055098D0 (no) Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser
NO20023448D0 (no) Medikamentkombinasjon for behandling av depresjon og beslektede forstyrrelser omfattende mirtazapin
NO20052264D0 (no) Pregahalinderivater for behandling av fibromyalgi og andre forstyrrelser
NO20052177D0 (no) Anvendelse av galantamin og dets derivater for fremstilling av legemidler
NO20043735L (no) Anvendelse av acylaminoalkenylenamidderivater ved funksjonelle motilitetsforstyrrrelser i innvollene
HRP20041159A2 (en) Combination for the treatment of airway disorders

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees